Abstract: A device is for surface strengthening of a metal plate based ultrasonic vibration is provided. The device includes an ultrasonic vibration tool holder and a cutting tool. The ultrasonic vibration tool holder is internally provided with an ultrasonic transducer and an ultrasonic booster; the ultrasonic transducer is configured to transmit vibration to the ultrasonic booster, the ultrasonic booster is configured to drive longitudinal torsion vibration of the cutting tool; an end of the ultrasonic booster facing towards the cutting tool is provided with an adjustment assembly configured for adjusting a longitudinal torsion angle and a rotation speed. Since the device includes the adjustment assembly, the longitudinal torsion angle and the rotation speed of the device can be adjusted according to different processing requirements, so as to perform ultrasonic vibration extrusion strengthening on surfaces of titanium alloy plates and improve surface integrity including microhardness and residual stress.

Abstract: A device is for surface strengthening of a metal plate based ultrasonic vibration. The device includes an ultrasonic vibration tool holder and a cutting tool. The ultrasonic vibration tool holder is internally provided with an ultrasonic transducer and an ultrasonic booster; the ultrasonic transducer is configured to transmit vibration to the ultrasonic booster, the ultrasonic booster is configured to drive longitudinal torsion vibration of the cutting tool; an end of the ultrasonic booster facing towards the cutting tool is provided with an adjustment assembly configured for adjusting a longitudinal torsion angle and a rotation speed. Since the device includes the adjustment assembly, the longitudinal torsion angle and the rotation speed of the device can be adjusted according to different processing requirements, so as to perform ultrasonic vibration extrusion strengthening on surfaces of titanium alloy plates and improve surface integrity including microhardness and residual stress.

Abstract: The disclosure relates to synthetic oligonucleotides that bind at least a portion of a dimerization initiation site (DIS) of a retrovirus genomic ribonucleic acid (RNA) molecule. In some aspects, the synthetic oligonucleotides include a 2?-deoxy-2?-fluoroarabinonucleotide (2?-FANA)-modified nucleotide sequence. In some embodiments, the 2?-FANA-modified nucleotide sequence inhibits dimerization of retroviral genomes (e.g., an HIV genome). Other embodiments include methods of inhibiting expression of a retrovirus using the synthetic oligonucleotide, and methods of treating or preventing a retroviral infection.

Abstract: The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).

Abstract: The present invention relates to novel c-MYC mRNA translation modulators, composition and methods of preparation thereof, and uses thereof in the treatment of cancer.

Abstract: The disclosure relates to synthetic oligonucleotides that bind at least a portion of a dimerization initiation site (DIS) of a retrovirus genomic ribonucleic acid (RNA) molecule. In some aspects, the synthetic oligonucleotides include a 2-deoxy-2-fluoroarabinonucleotide (2-FANA)-modified nucleotide sequence. In some embodiments, the 2-FANA-modified nucleotide sequence inhibits dimerization of retroviral genomes (e.g., an HIV genome). Other embodiments include methods of inhibiting expression of a retrovirus using the synthetic oligonucleotide, and methods of treating or preventing a retroviral infection.

Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.

Abstract: The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: The present invention is directed to 6-alkyl dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypo-function or basal ganglia dysfunction.